Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia.

Rembratt A, Riis A, Norgaard JP

Neurourology and urodynamics1 Jan 2006Cited by 81 (Europe PMC)

PMID16304673DOI10.1002/nau.20168PepBankPUB-16304673

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studySafety outcome
During desmopressin dose titration for nocturia, 95 patients (15%) had below-normal serum sodium.
In plain wordsDuring desmopressin dose titration for nocturia, 95 patients (15%) had low blood sodium.
Peptide
Desmopressin
Outcome
Not applicableBelow-normal serum sodium during titration
Study
n = 632
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Patients with below-normal serum sodium
95 patients
During dose titration
Patients with below-normal serum sodium
15%
During dose titration
Source sentences
Summary
During dose-titration, serum sodium concentration below normal range was recorded in 95 patients (15%) and 31 patients (4.9%) experienced significant hyponatremia.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467301
02HumanObservational studySafety outcome
During desmopressin dose titration for nocturia, 31 patients (4.9%) experienced significant hyponatremia.
In plain wordsDuring desmopressin dose titration for nocturia, 31 patients (4.9%) had blood sodium below 130 mmol/L.
Peptide
Desmopressin
Outcome
Not applicableSignificant hyponatremia during titration
Study
n = 632
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Patients with significant hyponatremia
31 patients
During dose titration
Patients with significant hyponatremia
4.9%
During dose titration
Source sentences
Summary
During dose-titration, serum sodium concentration below normal range was recorded in 95 patients (15%) and 31 patients (4.9%) experienced significant hyponatremia.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467302
03HumanObservational studySafety outcome
In desmopressin-treated nocturia patients, hyponatremia risk was linked to age, lower baseline sodium, higher basal urine volume per bodyweight and weight gain.
In plain wordsIn desmopressin-treated nocturia patients, low sodium risk was linked to age, lower initial sodium, higher urine volume and weight gain.
Peptide
Desmopressin
Outcome
IncreaseHyponatremia risk factors
Study
n = 632
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The risk increased with age, lower serum sodium concentration at baseline, higher basal 24-hr urine volume per bodyweight and weight gain at time of minimum serum sodium concentration.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467303
04HumanObservational studySafety outcome
In desmopressin-treated nocturia patients, age was the best single predictor of hyponatremia risk.
In plain wordsIn desmopressin-treated nocturia patients, age was the best single predictor of low sodium risk.
Peptide
Desmopressin
Outcome
Not applicableBest single risk predictor
Study
n = 632
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Age was the best single predictor.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467304
05HumanObservational studySafety outcome
In desmopressin-treated nocturia patients aged at least 65 years with low baseline sodium, hyponatremia risk was 75%.
In plain wordsIn desmopressin-treated nocturia patients aged at least 65 years with low initial sodium, low sodium risk was 75%.
Peptide
Desmopressin
Outcome
Not applicableRisk in older patients with low baseline sodium
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Hyponatremia risk
75%
Patients >=65 years with baseline serum sodium below normal range
Source sentences
Summary
Elderly patients (>or=65 years of age) with a baseline serum sodium concentration below normal range were at high risk (75%).
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467305
06HumanObservational studySafety outcome
In elderly nocturia patients with normal baseline sodium, restricting desmopressin to age below 79 years and urine output below 28 ml/kg would reduce hyponatremia risk from 8.1% to 3.0%.
In plain wordsIn elderly patients with normal sodium, limiting desmopressin by age and urine output would lower low-sodium risk from 8.1% to 3.0%.
Peptide
Desmopressin
Outcome
DecreaseRisk under proposed eligibility restrictions
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Hyponatremia risk without restriction
8.1%
Elderly with normal basal serum sodium
Hyponatremia risk with restriction
3%
Elderly with normal basal serum sodium, limited to age below 79 years and urine output below 28 ml/kg
Source sentences
Summary
Limiting treatment in elderly with normal basal serum sodium concentration to those below 79 years and with a 24-hr urine output below 28 ml/kg would reduce the risk from 8.1% to 3.0% at the cost of 34% fulfilling the contra-indication.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467306
07HumanObservational studyOther
In elderly nocturia patients with normal baseline sodium, age below 79 years and urine output below 28 ml/kg would exclude 34% from desmopressin.
In plain wordsIn older nocturia patients with normal initial sodium, proposed desmopressin restrictions would exclude 34%.
Peptide
Desmopressin
Outcome
Not applicableProportion excluded by eligibility restrictions
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Patients fulfilling the contra-indication
34%
Elderly with normal basal serum sodium, age limit 79 years and urine output limit 28 ml/kg
Source sentences
Summary
Limiting treatment in elderly with normal basal serum sodium concentration to those below 79 years and with a 24-hr urine output below 28 ml/kg would reduce the risk from 8.1% to 3.0% at the cost of 34% fulfilling the contra-indication.
3 context sentences(design, population, supporting numbers)
Summary · context
Data from three multi-center phase III trials were pooled.
Summary · context
Hyponatremia was categorised as borderline (134-130 mmol/L) or significant (<130 mmol/L).
Summary · context
In total 632 patients (344 men, 288 women) were analyzed.
Report a problemFND-1630467307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.